Last $126.64 USD
Change Today +0.13 / 0.10%
Volume 729.8K
RCPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

receptos inc (RCPT) Snapshot

Open
$129.86
Previous Close
$126.51
Day High
$130.47
Day Low
$125.27
52 Week High
12/23/14 - $139.40
52 Week Low
05/20/14 - $24.53
Market Cap
3.9B
Average Volume 10 Days
482.6K
EPS TTM
$-4.10
Shares Outstanding
31.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RECEPTOS INC (RCPT)

receptos inc (RCPT) Related Businessweek News

No Related Businessweek News Found

receptos inc (RCPT) Details

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that are in preclinical studies for the treatment of Type 2 diabetes. The company was formerly known as Receptor Pharmaceuticals, Inc. and changed its name to Receptos, Inc. in May 2009. Receptos, Inc. was founded in 2008 and is headquartered in San Diego, California.

41 Employees
Last Reported Date: 03/6/14
Founded in 2008

receptos inc (RCPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $451.6K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $254.8K
Chief Medical officer
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.

receptos inc (RCPT) Key Developments

Receptos, Inc. - Shareholder/Analyst Call

To discuss the results of positive Phase 2 trial of RPC1063 in Ulcerative Colitis

Receptos, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:25 PM

Receptos, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:25 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Faheem Hasnain, Chief Executive Officer, President and Director, Graham K. Cooper, Chief Financial Officer and Principal Accounting Officer.

Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis

Receptos, Inc. announced that the company has enrolled the first patient in the SUNBEAM Phase 3 trial of RPC1063 in patients with relapsing multiple sclerosis (RMS). The company had previously initiated the Phase 3 portion of the RADIANCE trial in patients with RMS. With both trials now actively enrolling patients, Receptos is on track to complete this Phase 3 clinical development program in 2017. The announcement follows the disclosure in September 2014 of the detailed Phase 2 results of RPC1063 in RMS. In that trial, RPC1063 met the primary endpoint of reduction in MRI brain lesion activity as well as secondary endpoints measuring effects on other MRI parameters. The overall safety profile of RPC1063 was consistent with the results of prior trials and continues to be differentiated on this basis from other oral agents for treatment of RMS. As with the RADIANCE trial, the SUNBEAM trial is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon beta-1a (Avonex®) in 1,200 patients with RMS. The primary objective for the RADIANCE and SUNBEAM trials is to assess whether RPC1063 is superior to Avonex® in reducing the annualized relapse rate in patients after two years of therapy and one year of therapy, respectively. Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) agreement with the FDA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCPT:US $126.64 USD +0.13

RCPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCPT.
View Industry Companies
 

Industry Analysis

RCPT

Industry Average

Valuation RCPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 512.8x
Price/Book 12.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 548.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECEPTOS INC, please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.